Clinicopathological Variables | Entire cohort (N = 47) | Non-recurrence (N = 40) | Recurrence (N = 7) |
---|---|---|---|
Age (Mean ± SD) | 47.6 ± 12.9 years | 48.6 ± 13.3 years | 39.7 ± 8.2 years |
Follow up (Median, IQR) | 80, 33.5 months | 85.5, 44.4 months | 27.1, 41.4 months |
Tumor type (N [%]) IDC ILC IMC | 42 (89.3%) 2 (4.3%) 3 (6.4%) | 36 (90%) 2 (5%) 2 (5%) | 6 (85.7%) 0 1 (14.3%) |
Breast Cancer subtype (N [%]) Hormone Receptor Positive (ER or PR) | 27 (57.4%) | 23 (57.5%) | 4 (57.1%) |
HER2-Receptor Positive | 24 (51.1%) | 21 (52.5%) | 3 (42.9%) |
Triple Negative Receptor | 8 (17.0%) | 7 (17.5%) | 1 (14.3%) |
RCB Index (N [%]) pCR Class I Class II Class III | 12 (25.5%) 10 (21.3%) 18 (38.3%) 7 (14.9%) | 12 (30%) 9 (22.5%) 16 (40%) 3 (7.5%) | 0 1 (14.3%) 2 (28.6%) 4 (57.1%) |
Recurrence (N [%]) | 7 (14.9%) | Â | Â |